[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100401867":3},{"organization":4,"outcomesModule":7,"designInfo":28,"detailedDescription":24,"studyPopulation":31,"armGroups":24,"interventions":32,"overallOfficials":24,"centralContacts":37,"locations":47,"responsibleParty":63,"collaborators":24,"id":65,"slug":24,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":24,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":24,"studyType":77,"phases":24,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":50,"whyStopped":24,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Beijing 302 Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":21,"otherOutcomes":24},[9,13,17],{"measure":10,"description":11,"timeFrame":12},"Overall survival time","OS is calculated starting from the date of SBRT to the date of the final follow-up or demise of the patients.","From date of randomization until the date of death from any cause, assessed up to 36 months",{"measure":14,"description":15,"timeFrame":16},"Progression-free survival time","PFS is estimated starting from the date of SBRT to the date of disease progression or patient death.","From date of randomization until the date of disease progression or date of death from any cause, whichever came first, assessed up to 36 months",{"measure":18,"description":19,"timeFrame":20},"Local control time","LC is defined starting from the date of SBRT to the date of treated-lesion progression or patient death.","From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months",[22,26],{"measure":23,"description":24,"timeFrame":25},"Radiation-induced liver injury rates",null,"From the date of radiotherapy completion until the 4 months after therapy,up to 6 months.",{"measure":27,"description":24,"timeFrame":25},"Adverse reaction",{"allocation":24,"interventionModel":24,"interventionModelDescription":24,"primaryPurpose":24,"observationalModel":29,"timePerspective":30,"maskingInfo":24},"COHORT","PROSPECTIVE","The small HCC patients with decompensated cirrhosis who refused or were ineligible for other treatments.",[33],{"type":34,"name":35,"description":36,"armGroupLabels":24,"otherNames":24},"RADIATION","Cyberknife stereotactic body radiation therapy","A total dose of 45-54 Gy in 5-10 fractions was given according to the location of lesions for small HCC patients with decompensated cirrhosis.",[38,43],{"name":39,"role":40,"phone":41,"phoneExt":24,"email":42},"Jing Sun","CONTACT","+8613718681094","519299998@qq.com",{"name":44,"role":40,"phone":45,"phoneExt":24,"email":46},"Xuezhang Duan","+8613621386161","duanxuezhang2006@163.com",[48],{"facility":49,"status":50,"city":51,"state":24,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Beijing 302 hospital","RECRUITING","Beijing","100039","China","CN",{"type":56,"coordinates":57},"Point",[58,59],116.39723,39.9075,{"lat":59,"lon":58},[62],{"name":44,"role":40,"phone":45,"phoneExt":24,"email":46},{"type":64,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100401867",false,"NCT04512833","CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma Patients With Decompensated Cirrhosis","CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Primary HCC diagnosed by a surgeon and\u002For radiologist and oncologist according to the international guidelines for the management of HCC or by pathology\n* Unfeasible or refusing to undergo other treatments;\n* Residual normal liver volume ≥700 cc;\n* With decompensated cirrhosis (Child-Pugh B or C classification);\n* Without portal vein tumor thrombus;\n* Eastern Cooperative Oncology Group (ECOG) score 0-1;\n* Distances between tumor and normal organs (esophagus, stomach, duodenum, bowel) are more than 5 mm；\n* Rejecting other therapies such as resection, liver transplantation, etc.\n* Platelet count≥50 × 109\u002FL, white blood count≥1.5 × 109\u002FL;\n* Patients infected with hepatitis B virus who are treated with adefovir or entecavir; patients infected with hepatitis C virus whose HCV DNA are negative.\n\nExclusion Criteria:\n\n* With Tumor thrombus；\n* With extrahepatic metastasis;\n* With lymph node involvement.","ALL","30 Years","80 Years",{"count":75,"type":76},60,"ESTIMATED","OBSERVATIONAL","The aim of our research is to evaluate the curative effect and safety of CyberKnife stereotactic body radiation therapy in treating small hepatocellular carcinoma (HCC) patients with decompensated cirrhosis.",[80],"Hepatocellular Carcinoma",[82,83,84,85,86],"hepatocellular carcinoma","CyberKnife","stereotactic body radiation therapy","Child-Pugh B classification","Child-Pugh C classification","2023-06-24",{"date":89,"type":90},"2023-06-27","ACTUAL",{"date":92,"type":90},"2020-08-12",{"date":94,"type":76},"2026-08-30",{"name":5,"class":6},1]